Galmed Pharmaceuticals Ltd (GLMD) concluded trading on Wednesday at a closing price of $0.43, with 17.31 million shares of worth about $7.44 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 18.78% during that period and on August 21, 2024 the price saw a gain of about 42.43%. Currently the company’s common shares owned by public are about 6.01M shares, out of which, 6.01M shares are available for trading.
Stock saw a price change of 49.04% in past 5 days and over the past one month there was a price change of 36.46%. Year-to-date (YTD), GLMD shares are showing a performance of -5.49% which decreased to -51.06% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.26 but also hit the highest price of $0.90 during that period. The average intraday trading volume for Galmed Pharmaceuticals Ltd shares is 48.32K. The stock is currently trading 45.06% above its 20-day simple moving average (SMA20), while that difference is up 40.50% for SMA50 and it goes to 19.37% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) currently have 6.01M outstanding shares and institutions hold larger chunk of about 6.60% of that.
The stock has a current market capitalization of $2.58M and its 3Y-monthly beta is at 0.68. It has posted earnings per share of -$1.82 in the same period. It has Quick Ratio of 6.34 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for GLMD, volatility over the week remained 15.23% while standing at 9.32% over the month.
EPS is likely to shrink at an annualized rate of 20.00% for next 5-years, compared to annual growth of 21.08% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley FBR on May 22, 2020 offering a Neutral rating for the stock and assigned a target price range of between $11 and $8 to it. Coverage by Craig Hallum stated Galmed Pharmaceuticals Ltd (GLMD) stock as a Buy in their note to investors on February 04, 2020, suggesting a price target of $18 for the stock. Stock get a Buy rating from B. Riley FBR on December 12, 2018.
